Last reviewed · How we verify

rituximab and everolimus

National Taiwan University Hospital · FDA-approved active Small molecule

rituximab and everolimus is a Monoclonal antibody + mTOR inhibitor combination Small molecule drug developed by National Taiwan University Hospital. It is currently FDA-approved for Antibody-mediated rejection in kidney transplant recipients, Autoimmune conditions with B cell involvement. Also known as: mabthera.

This combination uses rituximab to deplete B cells via CD20 targeting and everolimus to inhibit mTOR signaling, together suppressing immune activation and proliferation.

This combination uses rituximab to deplete B cells via CD20 targeting and everolimus to inhibit mTOR signaling, together suppressing immune activation and proliferation. Used for Antibody-mediated rejection in kidney transplant recipients, Autoimmune conditions with B cell involvement.

At a glance

Generic namerituximab and everolimus
Also known asmabthera
SponsorNational Taiwan University Hospital
Drug classMonoclonal antibody + mTOR inhibitor combination
TargetCD20 (rituximab); mTOR (everolimus)
ModalitySmall molecule
Therapeutic areaImmunology / Transplantation
PhaseFDA-approved

Mechanism of action

Rituximab is a chimeric monoclonal antibody that binds CD20 on B cell surfaces, leading to B cell depletion through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Everolimus is an mTOR inhibitor that suppresses T cell and B cell proliferation and activation. The combination targets both adaptive immune cell populations to reduce autoimmune and alloimmune responses.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about rituximab and everolimus

What is rituximab and everolimus?

rituximab and everolimus is a Monoclonal antibody + mTOR inhibitor combination drug developed by National Taiwan University Hospital, indicated for Antibody-mediated rejection in kidney transplant recipients, Autoimmune conditions with B cell involvement.

How does rituximab and everolimus work?

This combination uses rituximab to deplete B cells via CD20 targeting and everolimus to inhibit mTOR signaling, together suppressing immune activation and proliferation.

What is rituximab and everolimus used for?

rituximab and everolimus is indicated for Antibody-mediated rejection in kidney transplant recipients, Autoimmune conditions with B cell involvement.

Who makes rituximab and everolimus?

rituximab and everolimus is developed and marketed by National Taiwan University Hospital (see full National Taiwan University Hospital pipeline at /company/national-taiwan-university-hospital).

Is rituximab and everolimus also known as anything else?

rituximab and everolimus is also known as mabthera.

What drug class is rituximab and everolimus in?

rituximab and everolimus belongs to the Monoclonal antibody + mTOR inhibitor combination class. See all Monoclonal antibody + mTOR inhibitor combination drugs at /class/monoclonal-antibody-mtor-inhibitor-combination.

What development phase is rituximab and everolimus in?

rituximab and everolimus is FDA-approved (marketed).

What are the side effects of rituximab and everolimus?

Common side effects of rituximab and everolimus include Infection (bacterial, viral, fungal), Infusion reactions, Cytopenias, Hyperlipidemia, Renal dysfunction, Mouth ulcers.

What does rituximab and everolimus target?

rituximab and everolimus targets CD20 (rituximab); mTOR (everolimus) and is a Monoclonal antibody + mTOR inhibitor combination.

Related